RxDoctor Payments Data

Ashley Kinder, MD

Internal Medicine · Catonsville, MDNPI 1982920476

Payments from drug & device makers

$498in general payments, 2019–2025

Across 16 payments — averaging $31.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$134
  • Bayer$123
  • AstraZeneca$66
  • Merck$25
  • Takeda Pharmaceuticals U.S.A., Inc.$24
  • Amgen$22
  • plus $104 from 6 others

What the payments were for

  • Food & beverage$47996%
  • Education$194%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$498 in reported general payments places this provider in the 60th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$61,408
Medicare patients
199
Services billed
713

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide30$60,256
EliquisApixaban27$42,918
JardianceEmpagliflozin36$39,342
OzempicSemaglutide24$27,848
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$24,127
EntrestoSacubitril/Valsartan12$13,973
MyrbetriqMirabegron13$13,574
Rosuvastatin Calcium71$3,254
Atorvastatin Calcium227$2,922
Losartan Potassium97$1,507
Telmisartan11$1,360
Amlodipine Besylate112$1,237
Albuterol Sulfate HfaAlbuterol Sulfate25$1,194
SynthroidLevothyroxine Sodium18$1,032
Metoprolol Succinate45$939

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$14$88,10554 claims
Boehringer IngelheimJardiance$19$39,34236 claims
NovartisEntresto$134$13,97312 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$21$64556 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Catonsville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →